查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1936944

全球前列腺癌診斷市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Prostate Cancer Diagnostics Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 135 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計攝護腺癌診斷市場將從 2025 年的 102.7 億美元成長到 2034 年的 189.4 億美元，2026 年至 2034 年的複合年成長率為 7.04%。

受前列腺癌發病率上升和人們對早期檢測重要性認知不斷提高的推動，前列腺癌診斷市場預計將顯著成長。隨著全球人口老化，前列腺癌的盛行率預計將繼續上升，從而增加對有效診斷工具的需求。多參數磁振造影（MRI）和先進超音波等影像技術的創新正在提高前列腺癌檢測和鑑別的準確性。此外，包括前列腺特異性抗原（PSA）檢測和基因譜分析在內的基於生物標記的檢測方法的發展，正在改變前列腺癌的診斷格局，並推動前列腺癌個人化治療方案的發展。

技術進步也在塑造前列腺癌診斷市場的未來。將人工智慧 (AI) 和機器學習演算法整合到診斷影像中，提高了腫瘤檢測和風險分層的準確性。這些技術可以分析大量數據，識別傳統方法可能遺漏的模式和異常，最終實現更準確的診斷。此外，液態生物檢體技術的興起，為臨床醫生提供了一種非侵入性的疾病進展和治療反應監測方法，進一步增強了其診斷能力。

此外，隨著製藥公司和診斷設備製造商認知到前列腺癌檢測和治療方面尚未滿足的需求，加大研發投入將對前列腺癌診斷市場產生積極影響。學術機構、醫療服務提供者和產業相關人員之間的合作對於推動臨床試驗和將創新診斷解決方案推向市場至關重要。隨著監管機構不斷簡化新技術核准流程，重點將轉向將診斷技術整合到全面的前列腺癌治療方案中。這種整合將凸顯結合診斷見解和治療計劃的多方面方法的重要性，從而最佳化患者預後。隨著大眾對前列腺癌的認知不斷提高，促進篩檢和提高公眾意識的公共衛生措施將進一步推動對先進診斷工具的需求，最終有助於提高患者的生存率和生活品質。

目錄

第1章 引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場問題
  • 波特五力分析
  • PESTLE分析

第4章：全球前列腺癌診斷市場：依檢測類型分類

  • 市場分析、洞察與預測
  • 初步檢查
  • 確認性檢測

第5章 全球前列腺癌診斷市場：按類型分類

  • 市場分析、洞察與預測
  • 腺癌
  • 間質細胞癌
  • 其他

第6章：全球前列腺癌診斷市場：依最終用途分類

  • 市場分析、洞察與預測
  • 醫院
  • 門診部
  • 居家醫療
  • 研究/製造

第7章 全球前列腺癌診斷市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • MDx Health
    • Myriad Genetics Inc
    • Abbott Laboratories
    • F. Hoffman-La Roche AG
    • Bayer AG
    • Siemens Healthcare GmbH
    • OPKO Health Inc
    • Genomic Health
    • Pfizer Inc
簡介目錄
Product Code: VMR11213873

The Prostate Cancer Diagnostics Market size is expected to reach USD 18.94 Billion in 2034 from USD 10.27 Billion (2025) growing at a CAGR of 7.04% during 2026-2034.

The prostate cancer diagnostics market is poised for significant growth, driven by the increasing incidence of prostate cancer and the growing awareness of the importance of early detection. As the global population ages, the prevalence of prostate cancer is expected to rise, leading to a heightened demand for effective diagnostic tools. Innovations in imaging technologies, such as multiparametric MRI and advanced ultrasound techniques, are enhancing the accuracy of prostate cancer detection and characterization. Additionally, the development of biomarker-based tests, including prostate-specific antigen (PSA) testing and genetic profiling, is revolutionizing the diagnostic landscape, enabling personalized approaches to prostate cancer management.

Technological advancements are also shaping the future of the prostate cancer diagnostics market. The integration of artificial intelligence and machine learning algorithms into diagnostic imaging is improving the precision of tumor detection and risk stratification. These technologies can analyze vast amounts of data to identify patterns and anomalies that may be missed by traditional methods, ultimately leading to more accurate diagnoses. Furthermore, the rise of liquid biopsy techniques is providing a non-invasive alternative for monitoring disease progression and treatment response, further enhancing the diagnostic capabilities available to clinicians.

Moreover, the prostate cancer diagnostics market will benefit from increased investment in research and development, as pharmaceutical companies and diagnostic firms recognize the unmet needs in prostate cancer detection and management. Collaborative efforts between academic institutions, healthcare providers, and industry stakeholders will be crucial in advancing clinical trials and bringing innovative diagnostic solutions to market. As regulatory bodies continue to streamline approval processes for new technologies, the focus will shift towards integrating diagnostics into comprehensive prostate cancer care pathways. This integration will emphasize the importance of multidisciplinary approaches, combining diagnostic insights with treatment planning to optimize patient outcomes. As awareness of prostate cancer grows, public health initiatives aimed at promoting screening and education will further drive the demand for advanced diagnostic tools, ultimately contributing to improved survival rates and quality of life for patients.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Test Type

  • Preliminary Tests
  • Confirmatory Tests

By Type

  • Adenocarcinoma
  • Interstitial Cell Carcinoma
  • Other

By End Use

  • Hospitals
  • Outpatient Facilities
  • Home Care
  • Research & Manufacturing

COMPANIES PROFILED

  • MDx Health, Myriad Genetics Inc, Abbott Laboratories, F HoffmanLa Roche AG, Bayer AG, Siemens Healthcare GmbH, OPKO Health Inc, Genomic Health, Pfizer Inc

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET: BY TEST TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Test Type
  • 4.2. Preliminary Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Confirmatory Tests Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET: BY TYPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Type
  • 5.2. Adenocarcinoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Interstitial Cell Carcinoma Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET: BY END USE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast End Use
  • 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Outpatient Facilities Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Home Care Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Research & Manufacturing Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PROSTATE CANCER DIAGNOSTICS MARKET: BY REGION 2022-2034(USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Test Type
    • 7.2.2 By Type
    • 7.2.3 By End Use
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Test Type
    • 7.3.2 By Type
    • 7.3.3 By End Use
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Test Type
    • 7.4.2 By Type
    • 7.4.3 By End Use
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Test Type
    • 7.5.2 By Type
    • 7.5.3 By End Use
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Test Type
    • 7.6.2 By Type
    • 7.6.3 By End Use
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PROSTATE CANCER DIAGNOSTICS INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 MDx Health
    • 9.2.2 Myriad Genetics Inc
    • 9.2.3 Abbott Laboratories
    • 9.2.4 F. Hoffman-La Roche AG
    • 9.2.5 Bayer AG
    • 9.2.6 Siemens Healthcare GmbH
    • 9.2.7 OPKO Health Inc
    • 9.2.8 Genomic Health
    • 9.2.9 Pfizer Inc